Loading
Most cancer deaths are in low and middle income countries, where scans and endoscopies are scarce. A cheap methylation blood test tuned to liver, stomach, oesophageal, cervical and breast cancer could fill the gap.
Most cancer deaths occur in low and middle income countries where scans and endoscopies are scarce, so this idea develops a narrow-panel targeted-methylation blood test, run on low-cost sequencing or PCR, tuned to liver, stomach, oesophageal, cervical and breast cancer at a marginal cost of around ten dollars. Current MCEDs cost far more and target the US cancer mix; narrowing the target set and using PCR cuts cost, and liver and gastric cancers shed methylated DNA relatively well. A positive result would lead to ultrasound or endoscopy. The test is case-control development then a prospective 20,000-person cohort in a high-incidence region, with IARC as a partner. Speculative in maturity, it addresses The hardest cancers are found late and Most of the world has almost no cancer care.
Shares International Agency for Research on Cancer (IARC / WHO), Most of the world has almost no cancer care, Cervical cancer, Hepatocellular carcinoma.
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Early detection of cancer, The hardest cancers are found late, Gastric & gastro-oesophageal junction cancer.
Shares Early detection of cancer, Multi-cancer early detection (MCED), DNA methylation profiling, The hardest cancers are found late.
Shares Early detection of cancer, The hardest cancers are found late, Most of the world has almost no cancer care.
Shares Early detection of cancer, The hardest cancers are found late, Oesophageal cancer.
Shares Early detection of cancer, The hardest cancers are found late, Most of the world has almost no cancer care.
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.